Medexprim’s Post

If you are like me and cancer has somehow touched your life-It is easy to see why I’m so passionate about the research that we get to do. Oncology research is day by day, making big and impactful changes to the quality of care, treatment options, and ability to prolong progression free survival in so many cancer stages and tumor types, alike. Being such a small, but integral part of these every day changes, plus being able to contribute my ideas and experiences with the hope that it in some way continues to move Oncology clinical research in a forward direction. Improving not only the sites ability to succeed, but also the patient’s ability to have more access to clinical trials. #seeyouthere #scrsoncology

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

We’re Live! Our President & CEO, Mazhar Jaffry, is at the Oncology Site Solutions Summit! Don't miss the chance to see him in action during a panel discussion on "Tech-Driven Strategies for Site Excellence." Don’t miss out on this engaging session and explore how technologies are transforming clinical trials and how research sites can leverage them to achieve optimal performance. Gain valuable insights and hear Mazhar Jaffry share his expertise! #SCRS #Oncology #OncologyResearch #OncologySiteSolutionsSummit #TechnologyInClinicalTrials #ClinicalTrials #RevivalResearchInstitute

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Truqap to treat breast cancer that meets certain disease criteria. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/dw2U7yCr to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation

Here are some key takeaways from the CDDF webinar Clinical Research in Central and Eastern Europe in case you missed it :-) (https://lnkd.in/evsxJ6U8)

Diving into the dynamic landscape of Small Cell Lung Cancer (SCLC)

We are the proud sponsor of the I-SPY 2.2 TRIAL™, the latest evolution in the I-SPY series of trials for early breast cancer. The goal of I-SPY2.2 is very patient centered and straightforward - to find and develop biologically targeted treatments that help get each patient to the best possible outcome with the least toxicity (least side effects). QLHC board member and founder and Co-Principal Investigator of the I-SPY2.2 trial, Dr. Laura Esserman, said about the trial “I have spent much of my career trying to improve the outcomes of women with this early stage (potentially curable) aggressive breast cancer. I-SPY2.2 is the latest in the I-SPY family of trials and introduces a very patient friendly and straightforward trial design. Ultimately, the goal is to find and develop biologically targeted treatments that help get each patient to the best possible outcome, with the least toxicity. I firmly believe this trial is going to do just that.” You can learn more about us and the I-SPY trials, at https://lnkd.in/gWHmVyX9.  . . . #HealthcareForAll #InnovateHealthcare #PersonalizedMedicine #PatientCare #HealthEquity #HealthcareInnovation #BridgingResearchAndCare #IntegrityInHealthcare #CollaborativeCare #TransparencyInHealth #FutureOfHealthcare #ScienceAndCare #HealthcareLeadership #HealthForAll #MedicalInnovation #nonprofit #clinicaltrials #datacollection #healthdata #researchdata #diseaseresearch #findacure #nonprofit

Have a look (view) and a read on the report from m y colleague Gwyn: Our New Medicines, Novel Insights: Advancing Precision Oncology report, introduced by Dr. Gwyn Bebb, is a testament to our relentless pursuit of better patient outcomes. Our team of experts brings forward clinical trial expertise, regulatory insight, statistical acumen, advanced analytics capabilities and most importantly, patient perspectives. Dive in to explore how we’re pushing the boundaries of precision oncology. 💪 https://lnkd.in/ewvHgfZY #CancerResearch #Oncology #NovelInsights

Our New Medicines, Novel Insights: Advancing Precision Oncology report, introduced by Dr. Gwyn Bebb, is a testament to our relentless pursuit of better patient outcomes. Our team of experts brings forward clinical trial expertise, regulatory insight, statistical acumen, advanced analytics capabilities and most importantly, patient perspectives. Dive in to explore how we’re pushing the boundaries of precision oncology. 💪 #CancerResearch #Oncology #NovelInsights